Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Exclusion Criteria

• •Patients must not be pregnant and/or lactating.
• •Patients must not be receiving any other investigational agents.
• •No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic disease
• •Patients must not have received prior therapy (including radiation, surgery, and/or chemotherapy) within 30 days
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or vinorelbine.
• •Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed further with the study doctor.
• •Must not have uncontrolled illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmic, psychiatric illness/social situations that would limit compliance with study requirements.